Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — JP Morgan Healthcare Conference 2023
30 slides from Jb Chemicals & Pharmaceuticals's conference presentation, Jan 10, 2023
Slide 1: NSE filing cover letter for JP Morgan Healthcare Conference presentation
January 10, 2023 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Presentation at JP Morgan Healthcare Conference, SFO US Enclosed please find the presentation pro
Slide 2: JB Pharma - JP Morgan Healthcare Conference, SFO
JB Pharma (JB Chemicals & Pharmaceuticals Ltd) NSE : JBCHEPHARM BSE : JBCHEPHARM JP Morgan Healthcare Conference, SFO Tuesday, January 10, 2023 www.jbpharma.com jbpharma/ Jan 2023 JB Pharma 1
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Jan 2023 JB Pharma
Synergistic acquisitions Peak productivity Domestic outperformer @® ha} 24-26% Operating margin guidance Consistency of delivery Strong FCF Jor 00 EAN & Dosage fous + Global regulatory approvals Medicated/Herbal lozenges wwoimuteie & Leadership Key therapies Pillar Brands detship " “J.B. PHARMA “= O
Slide 5: Corporate Snapshot
Corporate Snapshot Brands among top 300 Increasing Share of the Domestic Years of operations with brands (IQVIA MAT Nov’22 46 consistent track record across multiple businesses 6 data), contributing over 60% of domestic formulations Revenue revenues 54% 56% 52% 46% Market Cap on INR 152 Growth in ch
Slide 6: Robust Manufacturing Infrastructure
® GOOD PEOPLE for GOOD HEALTH Robust Manufacturing Infrastructure
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 7 State of the Art manufacturing facilities 40+ Global Regulatory Accreditations 10 Producing a wide array of dosage forms Jan 2023 JB Pharma 6
Slide 8: FY22 highlights
17 key new product Key pillar brands - FY22 launches continue their market in FY22 with contribution beating 4% performance Growth in South Africa achieved International business record growth in FY22, despite external in public and private volatility market CMO Clientele Manufacturing New elite par
Slide 9: On track to delivering strategic objectives outlined
On track to delivering strategic objectives outlined Business Growth Productivity Stronger Improvement Governance Therapy Diversification Continuous thrust on improving Growth objectives supported Strengthening the Chronic productivity & cost structure by new management layer Portfolio and strong go
Slide 10: Domestic (India) Business
Domestic (India) Business Jan 2023 JB Pharma 9
Slide 11: Growth in Domestic business pivoted around key themes
Growth in Domestic(India) business pivoted around 4 key themes 1. Re-Aligned Go-To-Market model driving productivity 2. Making Big Brands Bigger 3. Increasing contribution from Chronic Therapies 4. Acquisition-led Growth, via strong brand franchises Jan 2023 JB Pharma 10
Slide 12: One of the fastest growing companies in its covered market
One of the fastest growing companies in its covered market; Consistently maintaining market beating performance Among top 25, JB is the fastest Leadership position Fastest Growing growing company in the IPM in the covered markets company among the 18% Top 25 in the India 35% Vs IPM growth + share in
Slide 13: 1. Re-Aligned Go-To-Market model driving productivity
1. Re-Aligned Go-To-Market model driving productivity Realignment of the Manpower leading to Accelerating Growth through new constant improvement in PCPM# Launches 0.6 New Introductions - % to Domestic Sales 0.4 4.0% 0.3 0.4 1.4% FY19 FY20 FY21 FY22 FY21 FY22 Monthly revenue per MR (INR Millions) 5
Slide 14: 2. Making Big Brands Bigger
2. Making Big Brands Bigger Rank in Rank in MS% in IPM* CVM* CVM* RANTAC #39 #2 6 major brands now feature in the Top 300 IPM Brands* 43% with a dominant share in their respective molecule segments CILACAR #47 #1 51% Re-Aligned GTM^ model, backed with lifecycle management / brand line-extensions
Slide 15: 3. Increasing contribution from Chronic Therapies
3. Increasing contribution from Chronic Therapies Contribution from Chronic vs Acute Therapies Chronic Therapy (%) Acute Therapy (%) • Consistently increasing contribution from Chronic Therapies • FY22 ended with 50% of Domestic sales from Chronic segment - 50% aided by launches in Heart-Failure, Di
Slide 16: 4. Acquisition-led growth, via strong brand franchises (1/3)
4. Acquisition-led growth, via strong brand franchises (1/3) • Completed Four Acquisitions in Calendar Year 2022 investing USD 200 mn • Judicious deployment of Capital and Free Cash flow in value-accretive brands and franchises Azmarda Paediatric portfolio • Extends our presence to the • Exciting ne
Slide 17: 4. Acquisition-led growth, via strong brand franchises (1/2)
4. Acquisition-led growth, via strong brand franchises (1/2) • Completed Four Acquisitions in Calendar Year 2022 investing USD 200 mn • Judicious deployment of Capital and Free Cash flow in value-accretive brands and franchises SANZYME AZMARDA Sizeable market opportunity in Heart-Failure (HF), ARNI#
Slide 18: 4. Acquisition-led growth, via strong brand franchises (2/2)
4. Acquisition-led growth, via strong brand franchises (2/2) • Completed Four Acquisitions in Calendar Year 2022 investing USD 200 mn • Judicious deployment of Capital and Free Cash flow in value-accretive brands and franchises Pediatric Brands from Dr. Reddys Razel (Rosuvastatin) Franchise from Gle
Slide 19: Domestic Business - on track towards achieving strategic priorities
Domestic Business - on track towards achieving strategic priorities WHEN WE STARTED CURRENT POSITION MID TO LONG-TERM OBJECTIVES IPM Position Ranked #32 in IPM Ranking 23rd In IPM Ranked in IPM Top 20 companies Contribution from ~45% of Domestic sales 50% of Domestic sales ~60% of Domestic sales Chr
Slide 20: International Business
International Business Jan 2023 JB Pharma 19
Slide 21: International Business: Distinct Operating Models Across Geographies
International Business: Distinct Operating Models Across Geographies International Business Revenues* 8920 mn 2530 mn 910 mn INR 12360 Mn Formulations CMO (Contract Mfg Operations) APIs *FY22 72% 21% 7% Jan 2023 JB Pharma 20
Slide 22: Leveraging leading position in Lozenges for future growth in Contract Manufacturing
Leveraging leading position in Lozenges for future growth in Contract Manufacturing(CMO) Contract Manufacturing Growth Levers Deeper penetration with existing Top 5 manufacturer of customers: explore new opportunities in medical/herbal lozenges & working more geographies with marquee global pharma/
Slide 23: H1 FY'23 Highlights
Delivering Value in Challenging Times H1 FY’23 Highlights Jan 2023 JB Pharma 22
Slide 24: A successful H1 FY23 delivery with healthy EBITDA margins
A successful H1 FY23 delivery with healthy EBITDA margins JB continued its strong growth momentum, registering YoY H1 FY23–Financial Overview growth of 33% in H1 FY23 Financial Performance 440 390 90 Total Revenue EBITDA* PAT 2100 1150 4870 1594 mn 1594 mn 1594 mn 4270 15940 mn 3920 mn 2160 mn H1 FY
Slide 25: Consistent Revenue/EBITDA growth over the years
Consistent Revenue/EBITDA growth over the years Domestic Formulations (INR mn) International Business (INR mn) Revenues (INR mn) CAGR: 19% CAGR: 11% CAGR: 14% 24240 11730 11270 12360 20430 9420 9540 17750 7970 8920 8530 8160 7410 14130 16430 15940 5880 6750 FY18 FY19 FY20 FY21 FY22 H1 FY18 FY19 FY20
Slide 26: JB Pharma: Outperforming the Nifty Pharma Index
JB Pharma : Outperforming the Nifty Pharma Index Close Price (NSE) 650 550 450 350 250 150 50 Dec-22 Jul-19 Jan-20 Jul-20 Jan-21 Jul-21 Jan-22 Jul-22 Oct-19 Oct-20 Oct-21 Oct-22 Apr-19 Apr-20 Apr-21 Apr-22 J B Chemicals & Pharmaceuticals (JB Pharma) Nifty Pharma Jan 2023 JB Pharma Slide No.: 25
Slide 27: JB publishes its First Sustainability Report - FY 2021-22
JB publishes its First Sustainability Report – FY 2021-22 Reporting Framework: Report prepared in accordance with the GRI Standards: Core Option, and United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the Company for the peri
Slide 28: JB Pharma - Looking ahead
JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform Continued growth momentum in International market growth driven by business Big brands becoming bigger Strong delivery in CMO business
Slide 29: Our New Identity
Our New Identity Jan 2023 JB Pharma 28
Slide 30: Thank you
Thank you Jan 2023 www.jbpharma.com JB Pharma 29
JB Chemicals & Pharmaceuticals — JP Morgan Healthcare Conference 2023 on 6ix